Hydroxychloroquine Pill

DRUG4 trials

Sponsors

Cairo University, Abramson Cancer Center at Penn Medicine, University of Calgary

Conditions

Colorectal Neoplasms MalignantCovid19DiarrheaKRAS Mutation-Related TumorsMultiple Sclerosis, Secondary ProgressiveNon-Small Cell Lung Cancer

Phase 1

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

TerminatedNCT04873895

Abramson Cancer Center at Penn MedicineColorectal Neoplasms Malignant

Start: 2022-01-24End: 2024-04-25Updated: 2024-04-26

Phase 2

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

CompletedNCT04735068

Abramson Cancer Center at Penn MedicineKRAS Mutation-Related Tumors, Non-Small Cell Lung Cancer

Start: 2021-04-09End: 2023-12-31Updated: 2025-04-01

Hydroxychloroquine and Indapamide in SPMS

University of CalgaryMultiple Sclerosis, Secondary Progressive

Start: 2021-10-01End: 2024-09-01Target: 35Updated: 2022-05-18

Unknown Phase

COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience

CompletedNCT04554979

Cairo UniversityCovid19, Diarrhea

Start: 2020-06-01End: 2020-07-15Updated: 2020-09-22

Related Papers

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer

The Oncologist2023-04-2618 citations